Angiogenic Gene Therapy (AGENT) Trial in Patients with Stable Angina Pectoris Cindy L. Grines William Beaumont Hospital, Royal Oak, Michigan, USA Previous investigations of ischemic heart disease in animal models have shown that successful angiogenesis improves regional blood flow and ventricular function. In this study, a single intracoronary administration of fibroblast growth factor 4 (FGF-4) to human patients with stable exertional angina was well tolerated and shown to be safe, and it produced beneficial anti-ischemic effects compared with administration of placebo. Reporter: Andre Weinberger, MD Copyright 2000-2013 by HESCO International, Ltd. All rights reserved.